WO2004089347A1 - Preparation pour absorption transdermique contenant du tulobuterol et timbre la contenant - Google Patents

Preparation pour absorption transdermique contenant du tulobuterol et timbre la contenant Download PDF

Info

Publication number
WO2004089347A1
WO2004089347A1 PCT/JP2004/004262 JP2004004262W WO2004089347A1 WO 2004089347 A1 WO2004089347 A1 WO 2004089347A1 JP 2004004262 W JP2004004262 W JP 2004004262W WO 2004089347 A1 WO2004089347 A1 WO 2004089347A1
Authority
WO
WIPO (PCT)
Prior art keywords
layer
absorption preparation
transdermal
patch
transdermal absorption
Prior art date
Application number
PCT/JP2004/004262
Other languages
English (en)
Japanese (ja)
Inventor
Takahito Kimura
Shigeto Fujishita
Takehiko Iwai
Original Assignee
Teika Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teika Pharmaceutical Co., Ltd. filed Critical Teika Pharmaceutical Co., Ltd.
Priority to JP2005505198A priority Critical patent/JP5512910B2/ja
Publication of WO2004089347A1 publication Critical patent/WO2004089347A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a transdermal absorption preparation containing rlobbuterol, and more particularly, to a transdermal absorption preparation containing rlobbuterol in a fine solid state without an excipient, and a patch using the same.
  • rolobuterol Since it has a sympathetic nerve stimulating action, it has been used as a bronchodilator for the treatment of respiratory distress due to airway obstruction such as bronchial asthma and emphysema.
  • This rolobuterol is used as an acid addition salt of rolobuterol hydrochloride as an oral preparation, but has been used as a percutaneous absorption agent in the form of a basic form of rolobuterol.
  • the above-mentioned excipients may include those that cause rash.
  • the contact area between the adhesive layer containing the excipients and the skin was reduced. (3) We had to deal with it by reducing the number of times of peeling and sticking.
  • the active ingredient dissolving layer is a layer containing a substance capable of dissolving or dispersing the active ingredient, and usually contains a good solvent for the active ingredient.
  • the present inventors have conducted intensive studies in view of the above circumstances, and as a result, even without using an excipient that has been considered to be necessary for dissolving allobutterol, that is, The inventors have found that allobuterol can be absorbed transdermally without the presence of an active ingredient dissolving layer between the skin and the skin, and completed the present invention.
  • the present invention provides a percutaneous absorption preparation in which allobuterol is carried in a fine solid state on the inside of the void or micropore formed by the fibrous or porous structure and / or on the surface of the structure.
  • the present invention also provides the above-mentioned percutaneous absorption preparation further containing a basic substance.
  • the present invention provides a patch comprising a substrate layer, an adhesive layer, and the above-mentioned transdermal absorption agent layer having an area smaller than that of the adhesive layer, which are laminated in this order.
  • FIG. 1 is a drawing schematically showing an example of the configuration of a patch using the transdermal preparation of the present invention.
  • the reference numerals in FIG. 1 are as follows.
  • FIG. 2 is a graph showing the concentration of ropopterol in plasma of the product of the present invention and the comparative product.
  • the fibrous structure used for the transdermal absorption preparation containing rlobbuterol of the present invention is not particularly limited, but has a form in which a woven fabric, a nonwoven fabric, a knitted fabric, fibers are simply shaped into a layer, or a paper form. Can be used. Preferred forms are woven, nonwoven or paper, and particularly preferred forms are nonwovens.
  • the material constituting the fibrous structure is not particularly limited, and various known materials can be used. Specifically, cellulose or its derivatives such as paper; fiber materials derived from plants such as cotton and hemp; fiber materials derived from animals such as silk and wool; inorganic materials such as glass fibers and metal fibers. Materials: Organic materials such as polyester, polyethylene, and polyamide are exemplified.
  • the porous structure used in the transdermal absorption preparation of the present invention is not particularly limited, but preferably has a form in which the pores are not isolated but continuous.
  • foaming resin open-cell type and non-open-cell type. Both types can be used in the present invention, but the open-cell type with good air permeability should be used in terms of skin irritation. Is desirable.
  • the material of the porous structure is not particularly limited, and various known materials can be used. Specific examples include polyurethane, polystyrene, polyethylene, silicone resin, polyvinyl chloride, polypropylene, polyester, polyamide, foamable metal, charcoal, cork, leather, natural rubber, and the like. Examples include polystyrene and polyethylene. Particularly preferred is polyurethane, and in combination with the above-mentioned form, continuous reading cell type foamable resin is particularly preferred.
  • ropterol needs to be supported inside the voids or micropores formed by the fibrous or porous structure (hereinafter referred to as “structure”) and / or on the surface of the structure. This support may be held simply by frictional force, or may be held by intermolecular force. Further, it may be directly attached to the material surface of the structure, or may be attached via an adhesive component.
  • a method for supporting allobuterol for example, a method of dissolving allobuterol in an appropriate solvent, applying this solution to the structure, and then drying, or a method of attaching finer allobuterol crystal powder to the structure And the like.
  • an adhesive component such as polyacrylic acid, polyvinyl alcohol, carboxyvinyl polymer, gelatin, gum arabic, methacrylic acid-methyl methacrylate copolymer (trade name: Eudragit L ⁇ s), a solution containing methacrylic acid-ethyl acrylate copolymer (trade name: Eudragit L30D), etc., is impregnated into the structure, which is then dried to make the material surface of the structure an adhesive component. After performing the process of covering with, butterol may be supported.
  • an adhesive component such as polyacrylic acid, polyvinyl alcohol, carboxyvinyl polymer, gelatin, gum arabic, methacrylic acid-methyl methacrylate copolymer (trade name: Eudragit L ⁇ s), a solution containing methacrylic acid-ethyl acrylate copolymer (trade name: Eudragit L30D), etc.
  • the solvent used for dissolving rlobbuterol is not particularly limited as long as it can dissolve the required amount of rlobbuterol in the formulation.
  • methanol, ethanol, isopropanol, acetone, and ethyl acetate are preferred from the viewpoint of worker safety and cost, and it is particularly desirable to use methanol, ethanol, and isopropanol.
  • the percutaneous absorption preparation of the present invention can contain a basic substance in order to increase the percutaneous absorption of ropopterol.
  • a basic substance can be used without particular limitation as long as it does not irritate the skin, regardless of whether it is an inorganic substance or an organic substance.
  • disodium hydrogen phosphate, sodium acetate, sodium hydrogen carbonate and the like can be used. Lithium and the like are particularly preferred.
  • the solvent for dissolving the above basic substance is not particularly limited, but water, methanol, ethanol, n-pentane, n-hexane, dimethyl ether, ethyl acetate, n-propanol,
  • a substance in which the basic substance is soluble can be selected from isopropanol, acetone, cyclopentane, cyclohexane, benzene, toluene, petroleum ether and the like. Above all, water is preferred from the viewpoint of cost and safety.
  • the average particle size of allobuterol supported on the structure is usually 5 Otm or less, and preferably 10 m or less in a fine solid state. If the average particle size of lobbuterol is larger than this, the holding power on the carrier may be insufficient, and lobbuterol may spill out of the structure to reduce the effect. Further, allobuterol may be attached to the structural material as a crystal or as an amorphous material.
  • the degree of persistence can also be controlled.
  • a method of adjusting the concentration of allobuterol to be carried on the structure a method of selecting a material of the structure, a method of selecting a fiber diameter or a pore diameter of the structure material, and the like are exemplified.
  • the percutaneous absorption preparation of the present invention thus obtained is not particularly limited as long as the structure supporting ropopterol can be brought into contact with the skin, and can be used as a dosage form such as a patch or a tape.
  • the transdermal absorption preparation of the present invention may be simply fixed with an adhesive tape or the like so as to be in contact with the skin.
  • a patch is taken as an example of a dosage form using the percutaneous absorption preparation of the present invention, and the configuration of the patch will be described with reference to the drawings.
  • FIG. 1 schematically shows the constitution of the patch of the present invention, wherein 1 is a substrate layer, 2 is an adhesive layer, 3 is a drug impermeable layer, 4 is a transdermal absorption preparation layer, and 5 is a protective film. Is shown.
  • a base layer 1 an adhesive layer 2, a drug-impermeable layer 3, and a transdermal absorption preparation layer 4 are laminated in this order.
  • the drug-impermeable layer 3 and the percutaneous absorption preparation layer 4 each have an area smaller than the pressure-sensitive adhesive layer 2, and the pressure-sensitive adhesive layer 2 is adhered to the skin or the like so as to enclose these layers.
  • the protective film 5 is sealed so as to cover the pressure-sensitive adhesive layer 2 and the transdermal absorption preparation layer 4.
  • the base material layer 1 is not particularly limited as long as it is a sheet-like material that can hold the pressure-sensitive adhesive layer 2 and the transdermal absorption preparation layer 4, and is used as a base material layer of a general pressure-sensitive adhesive tape. Can be used if they are available. For example, non-woven fabric, knit, polyester, etc. can be advantageously used.
  • the adhesive layer 2 is a layer for fixing the percutaneous absorption preparation layer 4 to the skin by its adhesive strength, and the type of the adhesive used is not limited as long as it has appropriate adhesiveness to the skin.
  • adhesives such as acrylic adhesives, rubber adhesives, and silicone adhesives are exemplified.
  • acrylic pressure-sensitive adhesives include methyl (meth) acrylate, ethyl (meth) acrylate, butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, vinyl acetate, methyl acetate, and methyl acetate.
  • the rubber-based adhesive examples include natural rubber, synthetic isoprene rubber, polyisobutylene rubber (PIB), polyvinyl ether, polyethylene, polyisoprene, polybutadiene, styrene-butadiene-styrene block copolymer (SBS). Styrene-isoprene copolymer, styrene-isoprene-styrene block copolymer (SIS), and the like. In particular, a styrene-isoprene-styrene block copolymer is preferable.
  • silicone-based pressure-sensitive adhesive examples include those containing a polyorganosiloxane such as polydimethylsiloxane as a main component.
  • the pressure-sensitive adhesive layer may contain a known tackifier or softener in addition to the above-mentioned pressure-sensitive adhesive.
  • a tackifier rosin-based rosin or rosin derivative hydrogenated, disproportionated, polymerized, or esterified
  • terpene resin such as 0! -Binene, ⁇ -pinene
  • terpene-phenol resin An aliphatic, aromatic, alicyclic, or copolymeric petroleum resin; alkyl-phenyl resin; xylene tree Fats and the like are used.
  • softener examples include higher fatty acid esters such as polybutene, liquid paraffin, liquid isoprene rubber, polyisobutylene, and isopropyl myristylate; silicon oil; almond oil, leabe oil, camellia oil, persic oil, or laccase oil. Vegetable oils, such as oils, are used, especially liquid barffins.
  • the drug-impermeable layer 3 is formed of the adhesive layer 2 and the percutaneously absorbable preparation layer 4 in order to prevent allobuterol from migrating to the adhesive layer 2 and reducing the concentration of allobuterol in the transdermal absorbent layer 4. Placed between.
  • the drug-impermeable layer 3 a known material which does not allow permeation of rlobbuterol and has a certain flexibility can be used. Specific examples include various plastic films, aluminum foils, and silicon resin films.
  • the area of the drug-impermeable layer 3 needs to be smaller than that of the adhesive layer 2 because it is necessary to attach the adhesive layer 2 to the skin. Also, because of the function of preventing contact between the percutaneously absorbable preparation layer 4 and the adhesive layer 2, the size of the percutaneously absorbable agent layer 4 is such that the area around the percutaneously absorbable agent layer 4 projects outside within a range of about 5 mm or less. It is preferable that From the viewpoint of manufacturability, it is particularly preferable that the size is the same as that of the transdermal absorption preparation.
  • the drug-impermeable layer 3 is omitted when the transfer of rolobuterol to the adhesive layer 2 is not so important or when an aqueous pressure-sensitive adhesive having low affinity with rolobuterol is used as the adhesive layer. Is also possible.
  • the percutaneous absorption preparation layer 4 is a layer in which allobuterol is retained, and is composed of the above-described embodiment and material.
  • the thickness of the percutaneous absorption preparation layer 4 is not particularly limited, but if it is too thin, the volume of the space for holding the drug is insufficient, so that it is not possible to hold a sufficient amount of the drug. 2 has wrinkles and inferior usability. Therefore, in a state where the structure is not compressed, the thickness is usually about 0.05 mm to 1 Omm, preferably 0.1 mm to 5 mm, and particularly preferably about 0.2 mm to 2 mm. It is desirable to have a thickness No.
  • a product in which a drug-impermeable layer and a drug-retaining layer are integrated in advance is commercially available (LMV-9004 / # 6A, manufactured by Japan Vilene Co., Ltd.). It can also be a patch.
  • the protective film 5 protects the preparation until use, and is peeled off during use.
  • various known materials can be used. Specific examples include films of polyethylene, polypropylene, polyester, polyvinyl acetate, polyvinyl chloride, polyurethane, and paper coated with silicon.
  • the mechanism of absorption of rlobbuterol in the present invention is not clear, but in the portion where rlobbuterol directly comes into contact with the skin, migration and absorption occur to the skin, and the drug holding layer is formed in such a manner as to compensate for the lack of concentration of rlobopterol near the skin. It is presumed that the mouthwater in the part of the skin that does not directly contact the skin moves to the vicinity of the skin at the molecular level.
  • Example 1 Example 1
  • Example 2 a commercially available adhesive tape (trade name: Registered trademark: TapeTape Scotch No. 8453 M) was cut into 5 cm x 5 cm, and the above-mentioned nonwoven fabric with the drug impermeable layer was cut thereon. The patch was adhered and arranged on the surface of the drug-impermeable layer, and further covered with a protective film to obtain a patch of the present invention.
  • a commercially available adhesive tape (trade name: Registered trademark: TapeTape Scotch No. 8453 M) was cut into 5 cm x 5 cm, and the above-mentioned nonwoven fabric with the drug impermeable layer was cut thereon.
  • the patch was adhered and arranged on the surface of the drug-impermeable layer, and further covered with a protective film to obtain a patch of the present invention.
  • Example 2
  • Example 5 Dissolve 100 mg of rolobuterol in methanol and mix with 10 mL of solution (7
  • Example 5 Example 5
  • the patches obtained in Examples 1 to 5 were subjected to a plasma concentration measurement test and a skin primary irritation test by the following methods.
  • a commercially available transdermal absorption-type allobuterol formulation (trade name: registered trademark Hocnarin (r) Tape 2 mg) in which allobuterol was dissolved in an excipient was used.
  • r registered trademark Hocnarin
  • a 7-week-old male hair resrat was preliminarily reared for one week and used in the experiment with a non-fasted body weight of around 260 g .
  • the results are shown in Table 1 and FIG.
  • the concentration of rlobbuterol in the plasma of Examples 1 to 4 was equal to or higher than that of the comparison, and the transdermal absorption preparation of the present invention has sufficient practicality. It turned out that.
  • the value of the plasma oral buterol concentration was higher in the time zone of 4 to 6 hr. As shown, it was possible to increase the absorption rate by adding a basic substance. ⁇ Skin primary irritation test>
  • Example 5 Although the amount of absorption was small, a certain amount of absorption was observed. It can be assumed that a sufficient amount of the drug can be absorbed by adjusting the concentration of rolobuterol per unit area, and that the skin irritation is excellent as in Example 2. It is better than the comparative example. Industrial applicability
  • the present invention it is possible to provide a percutaneous absorption preparation having a completely new absorption mechanism by adhering allobuterol to the space (voids or micropores) or the surface inside the fibrous or porous structure. is there.
  • a transcutaneous absorption preparation containing no excipients which simplifies the production process, reduces cost, and reduces skin irritation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une préparation pour absorption transdermique, caractérisée en ce que le tulobutérol est chargé sous forme d'articles solides, fins, dans les interstices d'une structure fibreuse ou poreuse, à l'intérieur de petits pores et/ou dans la surface de la structure. Bien que cette préparation pour absorption transdermique contenant du tulobutérol ne contienne pas d'excipient provoquant des irritations de la peau, elle présente de bonnes caractéristiques d'absorption transdermique. Ainsi, selon l'invention, la préparation pour absorption transdermique contenant du tulobutérol irritant moins la peau peut être produite, tout en simplifiant le processus de production et en réduisant les coûts de main d'oeuvre.
PCT/JP2004/004262 2003-04-10 2004-03-26 Preparation pour absorption transdermique contenant du tulobuterol et timbre la contenant WO2004089347A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005505198A JP5512910B2 (ja) 2003-04-10 2004-03-26 ツロブテロール含有経皮吸収製剤およびこれを使用する貼付剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-106239 2003-04-10
JP2003106239 2003-04-10

Publications (1)

Publication Number Publication Date
WO2004089347A1 true WO2004089347A1 (fr) 2004-10-21

Family

ID=33156905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004262 WO2004089347A1 (fr) 2003-04-10 2004-03-26 Preparation pour absorption transdermique contenant du tulobuterol et timbre la contenant

Country Status (2)

Country Link
JP (1) JP5512910B2 (fr)
WO (1) WO2004089347A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006124339A (ja) * 2004-10-29 2006-05-18 Teika Seiyaku Kk 経皮吸収製剤
JP2010155810A (ja) * 2008-12-29 2010-07-15 Nitto Denko Corp 軟膏貼付剤
WO2021079795A1 (fr) * 2019-10-21 2021-04-29 株式会社メドレックス Patch transdermique stratifié
CN114269330A (zh) * 2019-06-28 2022-04-01 帕斯帕特技术有限公司 透皮药物递送贴片、药物递送系统和药物递送方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199659A (ja) * 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
JPH07285854A (ja) * 1994-04-14 1995-10-31 Nitto Denko Corp 経皮吸収型製剤
WO1997014411A1 (fr) * 1995-10-17 1997-04-24 Nitto Denko Corporation Preparation a base de tulobuterol administrable par voie transcutanee et son procede de production
JPH11302161A (ja) * 1998-04-17 1999-11-02 Hisamitsu Pharmaceut Co Inc 貼付製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156843A (en) * 1989-03-20 1992-10-20 Advanced Polymer Systems, Inc. Fabric impregnated with functional substances for controlled release
JPH02280772A (ja) * 1989-04-24 1990-11-16 Descente Ltd 経皮薬物徐放被服材
JP2926678B2 (ja) * 1995-06-30 1999-07-28 小島プレス工業株式会社 自動変速機用シフトレバー装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199659A (ja) * 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
JPH07285854A (ja) * 1994-04-14 1995-10-31 Nitto Denko Corp 経皮吸収型製剤
WO1997014411A1 (fr) * 1995-10-17 1997-04-24 Nitto Denko Corporation Preparation a base de tulobuterol administrable par voie transcutanee et son procede de production
JPH11302161A (ja) * 1998-04-17 1999-11-02 Hisamitsu Pharmaceut Co Inc 貼付製剤

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006124339A (ja) * 2004-10-29 2006-05-18 Teika Seiyaku Kk 経皮吸収製剤
JP2010155810A (ja) * 2008-12-29 2010-07-15 Nitto Denko Corp 軟膏貼付剤
CN114269330A (zh) * 2019-06-28 2022-04-01 帕斯帕特技术有限公司 透皮药物递送贴片、药物递送系统和药物递送方法
EP3989950A4 (fr) * 2019-06-28 2023-07-19 PassPort Technologies, Inc. Timbre d'administration de médicament transdermique, système d'administration de médicament et procédé d'administration de médicament
WO2021079795A1 (fr) * 2019-10-21 2021-04-29 株式会社メドレックス Patch transdermique stratifié
EP4049655A4 (fr) * 2019-10-21 2023-12-06 MEDRx Co., Ltd. Patch transdermique stratifié

Also Published As

Publication number Publication date
JPWO2004089347A1 (ja) 2006-07-06
JP5512910B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
JP2700835B2 (ja) アクリル系ゲル材およびアクリル系ゲル製剤
JP4809062B2 (ja) カバー材及びカバー材付き貼付剤
US9656441B2 (en) Transdermal patch
US20060193900A1 (en) Pressure sensitive adhesive and patch
CA2208132A1 (fr) Systeme de liberation transdermique avec opercule adhesif et rondelle pelable
JP2013237691A (ja) 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法
EP1225951A2 (fr) Systeme de relargage double de medicaments par voie transdermique a couches adhesives
JP2008507495A (ja) 活性本体の経皮送達用デバイス
JP2002531488A (ja) 揮発性液体薬剤を送出するための経皮パッチ
KR20160005024A (ko) 리바스티그민을 포함하는 경피 약물 전달체
KR100473677B1 (ko) 물리적 특성이 향상된 폴리아크릴레이트 매트릭스를 구비한 경피 또는 국소 플래스터 시스템
AU2010274374A1 (en) Fentanyl-containing adhesive preparation for external use
KR20200015929A (ko) 경피 흡수형 제제
ES2872725T3 (es) Sistema terapéutico transdérmico con una sobrecubierta que comprende dos capas adhesivas
JPH06199659A (ja) 経皮治療用装置
JP5512910B2 (ja) ツロブテロール含有経皮吸収製剤およびこれを使用する貼付剤
JP4136029B2 (ja) 硝酸イソソルビド含有貼付剤
JPH0623029A (ja) アクリル系ゲル材およびアクリル系ゲル製剤
WO1998051288A1 (fr) Preparations de patch destinees a etre absorbees par voie percutanee
JP4889172B2 (ja) 水分感応性経皮吸収型製剤
JPWO2004112770A1 (ja) ツロブテロール含有貼付剤
JP2003104874A (ja) 放出制御型薬物投与デバイス
JPH05305108A (ja) 貼付剤の包装構造
JPH07215847A (ja) 眠気防止用テープ
JP2003104875A (ja) 放出遅延型薬物投与デバイス

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005505198

Country of ref document: JP

122 Ep: pct application non-entry in european phase